Australian pharmaceutical
research received a boost yesterday
with the announcement of a
major deal between the Australian
biotech firm and Merck, to finance
the development of small molecule
candidates for pain therapy.
The deal, worth up to $172m,
gives Merck the option to
exclusively license a compound
from Bionomics for development
and commercialisation.
Bionomics will use its ionX drug
discovery platform and MultiCore
chemistry to identify potential
candidate molecules.
The initial period of the research
program will be two years.
Investigations will cover both
chronic and neuropathic pain, with
the global pain treatment market
estimated to be worth around
US$19 billion annually.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Aug 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Aug 13
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.